Nanda R, Liu MC, Yau C, et al.

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

.

JAMA Oncol

10.1001/jamaoncol.2019.6650

:

, 

2020

.

Chien AJ, Tripathy D, Albain KS, et al.

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial

.

J Clin Oncol

doi.org/10.1200/JCO.19.01027

:

, 

2020

.

Piawah S, Hyland C, Umetsu SE, et al.

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel

.

npc Breast Cancer

5

:

17

, 

2019

.

Li W, Newitt DC, Wilmes LJ, et al.

Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL

.

J Magn Reson Imaging

:

, 

2019

.

Esserman L, Hylton N, Asare S, et al.

I-SPY2: Unlocking the Potential of the Platform Trial

. In 

Z. Antonijevic & R. A. Beckman

 (Eds.), 

Platform Trial Designs in Drug Development: Umbrella Trials and Basket Trials

(

Chapman and Hall/CRC

); pp.

3-22

, 

2018

.

Newitt DC, Zheng Z, Gibbs JE, et al.

Test–retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial

.

J Mag Res Imag

49

:

1617-1628

, 

2019

.

Partridge SC, Zhang Z, Newitt DC, et al

Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial

.

Radiol

0

:

1-11

, 

2018

.

Boughey JC, Alvarado MD, Lancaster RB, et al.

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

.

npj Breast Cancer

4

:

26

, 

2018

.

Wulfkuhle JD, Yau C, Wolf DM, et al

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL

.

JCO Precision Oncology

:

1-20

, 

2018

.

Scheel JR, Kim E, Partridge SC, et al.

MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial

.

Am J Roentgenol

210

:

1376-1385

, 

2018

.

Olshen A, Wolf D, Jones EF, et al.

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL

.

J Med Imaging

5

:

11014

, 

2018

.

Wolf DM, Yau C, Sanil A, et al.

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial

.

npj Breast Cancer

3

:

, 

2017

.

Severson TM, Wolf DM, Yau C, et al.

The BRCA1 ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

.

Breast Cancer Res

19

:

99

, 

2017

.

Campbell JI, Yau C, Krass P, et al.

Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

.

Breast Cancer Res Treat

165

:

181-191

, 

2017

.

Li W, Arasu V, Newitt DC, et al.

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.

.

Tomography

2

:

378-387

, 

2016

.

Rugo HS, Olopade, OI, DeMichele A, et al.

Adaptive randomization of veliparib-carboplatin treatment in breast cancer

.

New Engl J Med

375

:

23-34

, 

2016

.

Park JW, Liu MC, Yee D, et al.

Adaptive Randomization of Neratinib in Early Breast Cancer

.

N Engl J Med

375

:

11-22

, 

2016

.

Magbanua MJM, Wolf DM, Yau C, et al.

Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response

.

Breast Cancer Res

17

:

73

, 

2015

.

DeMichele A, Yee D, Berry D, et al.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

.

Clinical Cancer Research

21

:

2911-2915

, 

2015

.

Price ER, Wong J, Mukhtar R, et al

How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer

.

World J Clinical Cases

3

:

607-613

, 

2015

.

Clark AS, Chen J, Kapoor S, et al.

Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I‐SPY trial (CALGB 150007/150015/ACRIN6657)

.

Cancer Medicine

3

:

693-701

, 

2014

.

Cureton EL, Yau C, Alvarado MD, et al.

Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

.

Ann Surg Oncol

21

:

2889-2896

, 

2014

.

Alvarez JV, Pan T-C, Ruth J, et al.

Par-4 Downregulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy

.

Cancer Cell

24

:

30-44

, 

2013

.

Mukhtar RA, Yau C, Rosen M, et al.

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

.

Ann Surg Oncol

20

:

3823-3830

, 

2013

.

DeMichele A, Berry DA, Zujewski J, et al.

Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials

.

Clinical Cancer Research

19

:

2817-2823

, 

2013

.

Glück S, de Snoo F, Peeters J, et al.

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.

.

Breast Cancer Res Treat

139

:

759-767

, 

2013

.

Yee D, Haddad T, Albain K, et al.

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development [Correspondence]

.

J. Clin. Oncol.

30

:

Jun-84

, 

2012

.

Esserman LJ, Barker AD, Woodcock J, et al.

A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents

.

Cureus

4

:

e76

, 

2012

.

Wulfkuhle JD, Berg D, Wolff C, et al.

Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping

.

Clinical Cancer Research

18

:

6426-6435

, 

2012

.

Esserman LJ, Berry DA, DeMichele A, et al.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657

.

J Clin Oncol

30

:

3242-3249

, 

2012

.

Lips EH, Mukhtar RA, Yau C, et al.

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer

.

Breast Cancer Res Treat

136

:

35-43

, 

2012

.

Hylton NM, Blume JD, Bernreuter WK, et al.

Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL

.

Radiology

263

:

663-672

, 

2012

.

Esserman LJ, Berry DA, Cheang MCU, et al.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

.

Breast Cancer Res Treat

132

:

1049-1062

, 

2012

.

Lin C, Buxton MB, Moore D, et al.

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)

.

Breast Cancer Res Treat

132

:

871-879

, 

2012

.

Esserman LJ, Woodcock J

Accelerating identification and regulatory approval of investigational cancer drugs

.

JAMA

306

:

2608-2609

, 

2011

.

Perlmutter, J

Advocate Involvement in I-SPY 2

.

Breast Disease: A Year Book Quarterly

22

:

21-24

, 

2011

.

Barker AD, Sigman CC, Kelloff GJ, et al.

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

.

Clinical Pharmacol & Therapeutics

86

:

97-100

, 

2009

.